| 產(chǎn)品描述： | DBPR108 is an orally bioavailable dipeptide-derived DPP4 inhibitor (IC50: 15 nM) and it has no inhibition on DDP8 and DPP9. |
| 靶點： |
DPP-4;Proteasome;Proteasome;?DPP-4 |
| 體外研究： |
DBPR108 displays a more than 3000-fold selectivity over DPP8 DPP9, FAP and DPP-II. |
| 體內(nèi)研究： |
DBPR108 is a potent, selective, long-acting and safe DPP-IV inhibitor as a potential treatment of type 2 diabetes mellitus. The in vivo effects of DBPR108, including inhibition of plasma DPP-IV activity and suppression of blood glucose elevation, were also demonstrated. |
| 參考文獻： |
1. Yeh TK, et al. (2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV. Bioorg Med Chem Lett. 2010 Jun |
| 溶解性： |
soluble in DMSO |
| 保存條件： |
-20℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
3.083 ml |
15.413 ml |
30.827 ml |
| 5 mM |
0.617 ml |
3.083 ml |
6.165 ml |
| 10 mM |
0.308 ml |
1.541 ml |
3.083 ml |
| 50 mM |
0.062 ml |
0.308 ml |
0.617 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京